SpringWorks Therapeutics (SWTX)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$0.27 (-0.63%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of SpringWorks Therapeutics (SWTX)
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.

Key Insights

Critical company metrics and information

  • Share Price

    $42.31

  • Market Cap

    $3.15 Billion

  • Total Outstanding Shares

    74.39 Million Shares

  • Total Employees

    305

  • Dividend

    No dividend

  • IPO Date

    September 13, 2019

  • SIC Description

    Biological Products, (no Disgnostic Substances)

  • Homepage

    https://www.springworkstx.com

Historical Stock Splits

If you bought 1 share of SWTX before March 17, 2011, you'd have 0.20 shares today.
Execution DateSplit Amount
March 17, 20111-for-5 (Reverse Split)

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities$-108.81 Million
Net Cash Flow From Financing Activities, Continuing$303.18 Million
Net Cash Flow From Financing Activities$303.18 Million
Net Cash Flow From Operating Activities$-208.80 Million
Net Cash Flow, Continuing$-14.43 Million
Net Cash Flow$-14.43 Million
Net Cash Flow From Investing Activities, Continuing$-108.81 Million
Net Cash Flow From Operating Activities, Continuing$-208.80 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Income/Loss From Continuing Operations Before Tax$17.81 Million
Net Income/Loss$-275.16 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Income/Loss From Equity Method Investments$-6.45 Million
Operating Expenses$423.32 Million
Income/Loss From Continuing Operations After Tax$-275.16 Million
Diluted Earnings Per Share$3.89
Selling, General, and Administrative Expenses$239.39 Million
Diluted Average Shares$148.95 Million
Operating Income/Loss$-295.25 Million
Revenues$135.49 Million
Nonoperating Income/Loss$26.54 Million
Basic Average Shares$148.95 Million
Income/Loss Before Equity Method Investments$-90.68 Million
Cost Of Revenue$7.42 Million
Research and Development$183.93 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Preferred Stock Dividends And Other Adjustments$0.00
Net Income/Loss Attributable To Parent$-275.16 Million
Basic Earnings Per Share$3.89
Net Income/Loss Available To Common Stockholders, Basic$-275.16 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Current Liabilities$70.61 Million
Equity Attributable To Noncontrolling Interest$0.00
Assets$608.88 Million
Accounts Payable$9.65 Million
Other Current Liabilities$40.65 Million
Wages$20.31 Million
Current Assets$435.11 Million
Inventory$9.83 Million
Noncurrent Assets$173.77 Million
Noncurrent Liabilities$5.68 Million
Equity$532.58 Million
Equity Attributable To Parent$532.58 Million
Cash$498.10 Million
Liabilities$76.30 Million
Fixed Assets$19.34 Million
Other Non-current Assets$154.43 Million
Liabilities And Equity$608.88 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
Earnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

ⓒ 2024 Financhle. All Rights Reserved.